Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.900
+0.030 (1.60%)
Nov 4, 2024, 4:00 PM EST - Market closed

Cardiol Therapeutics Income Statement

Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2017
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2017
Revenue
---0.08--
Upgrade
Gross Profit
---0.08--
Upgrade
Selling, General & Admin
19.1815.5622.3727.8710.094.95
Upgrade
Research & Development
12.6514.2218.9610.8710.63.53
Upgrade
Operating Expenses
31.8329.7941.3438.7420.6911.89
Upgrade
Operating Income
-31.83-29.79-41.34-38.66-20.69-11.89
Upgrade
Interest Expense
------0
Upgrade
Interest & Investment Income
1.652.041.240.110.080.25
Upgrade
Currency Exchange Gain (Loss)
0.82-0.712.761.89-0.03-0.1
Upgrade
Other Non Operating Income (Expenses)
0.020.336.415.030.01-1.94
Upgrade
Pretax Income
-29.34-28.13-30.93-31.64-20.64-13.68
Upgrade
Net Income
-29.34-28.13-30.93-31.64-20.64-13.68
Upgrade
Net Income to Common
-29.34-28.13-30.93-31.64-20.64-13.68
Upgrade
Shares Outstanding (Basic)
666463433026
Upgrade
Shares Outstanding (Diluted)
666463433026
Upgrade
Shares Change (YoY)
4.44%3.13%44.61%44.77%15.63%67.97%
Upgrade
EPS (Basic)
-0.44-0.44-0.49-0.73-0.69-0.53
Upgrade
EPS (Diluted)
-0.44-0.44-0.49-0.73-0.69-0.53
Upgrade
Free Cash Flow
-21.6-25.24-27.3-23.55-9.17-11.8
Upgrade
Free Cash Flow Per Share
-0.33-0.39-0.44-0.54-0.31-0.46
Upgrade
Gross Margin
---100.00%--
Upgrade
Operating Margin
----49091.93%--
Upgrade
Profit Margin
----40170.45%--
Upgrade
Free Cash Flow Margin
----29904.22%--
Upgrade
EBITDA
-31.66-29.59-41.16-38.44-20.46-11.77
Upgrade
D&A For EBITDA
0.170.20.180.220.230.13
Upgrade
EBIT
-31.83-29.79-41.34-38.66-20.69-11.89
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.